Wild F
Wissenschaftlichen Institut der PKV (WIP), Köln.
Versicherungsmedizin. 2009 Dec 1;61(4):159-62.
In this paper the author analyses the prescription of pharmaceuticals for elderly private insured persons. Data from eight firms form the basis of the survey. The main focus lies in the analysis of the expenditure per capita and the distribution of the pharmaceuticals costs. It will illustrate that costs for elderly private insured persons will have a great impact on the expenditure for the private health insurance companies in the coming years.
